Manufactured in Belgium by a division of Pfizer
The peptide has a relatively short half-life of approximately 20 minutes, meaning it clears the body quickly while stimulating growth hormone release that lasts much longer
Clinical trial data referenced in this article reflects outcomes from large clinical trials of FDA-approved branded medications and does not represent BreezeMeds-specific outcomes or guaranteed results for compounded formulations
The research, Gastroparesis (GP) Risk in Patients with Type 2 Diabetes (T2D) Prescribed GLP-1 Receptor Agonists, was recently presented during the Digestive Disease Week Conference
However, like all medical treatments, results vary by patient and the results cannot be guaranteed
(online ahead of print) [DOI] [Google Scholar] [47].Sayed NH, Fathy N, Kortam MA, Rabie MA, Mohamed AF, Kamel AS